Shell-vial culture and pp65 antigenemia assay in the detection of cytomegalovirus in the first blood sample of renal transplant recipients.
The aim of the study was to compare the efficacy of pp65 antigenemia assay and the shell-vial culture (SVC; viremia) for the diagnosis of cytomegalovirus (CMV) infection in renal transplant recipients, comparing the results obtained in the first blood sample and the total number of blood samples analyzed in this group of patients. During the study period, 70 renal transplant recipients were studied: 44 (62.8%) with CMV infection. The method of sedimentation in a dextran solution for leukocyte extraction was used in the pp65 antigenemia assay. The MRC-5 shell-vial assay was used for CMV isolation from leukocytes (viremia). Eighty blood samples were examined from 70 renal transplant recipients: Of the 44 positive samples studied, in 77.5% of cases, both the antigenemia assay and the SVC were positive. In 16.2%, only the antigenemia assay was positive, and, in 6.2%, only the SVC was positive. In all blood samples studied, the antigenemia was present in 93.7% of cases, and the SVC was present in 83.7% (P = 0.04). If the results obtained in only the first blood sample taken for the diagnosis are studied, then we observe that the antigenemia assay was positive in 39 patients (88.6%), whereas the SVC was positive in 41 patients (93.1%), although the difference was not statistically significant (P = 0.39). It is concluded that the inoculation of all of the leukocytes extracted from blood samples in the SVC seems to produce a slight increase in the sensitivity of the cell culture and that the SVC becomes positive before the antigenemia for the detection of CMV in peripheral blood, especially in the first blood sample.
Reina
J
J
Virology Unit, University Hospital Son Dureta, Universitat Illes Balears, Palma de Mallorca, Spain.
Fernandez-Baca
V
V
Saurina
J
J
Blanco
I
I
Munar
M
M
D000911:Antibodies, Monoclonal; D000956:Antigens, Viral / Q000097:blood*; D003470:Culture Media; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000175:diagnosis*; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D010750:Phosphoproteins / Q000097:blood*; D011446:Prospective Studies; D014763:Viral Matrix Proteins / Q000097:blood*; D014766:Viremia / Q000175:diagnosis / Q000821:virology
D000911:Antibodies, Monoclonal; D000956:Antigens, Viral; D003470:Culture Media; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa